金城医药：子公司两款产品收到药品注册证书

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received drug registration certificates for two products, enhancing the company's product line and experience for future R&D [1] Group 1: Product Approval - Jincheng Pharmaceutical's wholly-owned subsidiary, Jincheng Tail and Jincheng Suzhih, received drug registration certificates from the National Medical Products Administration for Bisoprolol Amlodipine Tablets and Cefdinir Dry Suspension [1] - Bisoprolol Amlodipine Tablets serve as an alternative therapy for hypertension, while Cefdinir Dry Suspension is an oral antibiotic [1] Group 2: Impact on Company - The approval of these two products will further enrich the company's product line [1] - The experience gained from these approvals will contribute to the R&D of other products in the future [1]